"Isn't That Cheating?" — Why That's the Wrong Question About GLP-1 and GIP Medications
If you've spent any time around gyms, group chats, or social media lately, you've probably heard some version of it: "They just took the easy way out." "That's cheating." "Real weight loss should come from diet and exercise."
It's a common reaction to semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and the broader class of GLP-1/GIP medications. And I understand where it comes from — for decades, weight loss has been framed as a pure test of willpower. But as a clinician, I want to walk through why that framing doesn't hold up, and more importantly, why I think it's actively costing some people access to genuinely life-changing, evidence-backed treatment.
Let's Try the Same Logic on Blood Pressure
Here's a thought experiment. Imagine someone with high blood pressure. Their doctor could tell them: reduce sodium, lose weight, cut back on alcohol, exercise regularly. Would that work? Often, yes — and impressively well. A combination of the DASH diet, sodium reduction, and consistent exercise can lower systolic blood pressure by 20 to 30 mmHg in some patients — enough to normalize many cases of stage 1 hypertension entirely.
So if lifestyle changes alone can control blood pressure that effectively, is it "cheating" to prescribe a blood pressure medication instead — or alongside those changes?
Nobody actually thinks that. We don't tell hypertensive patients they're taking a shortcut when they fill an ACE inhibitor prescription. We recognize that lifestyle change is genuinely powerful, that it's worth encouraging, and that medication isn't a replacement for it — but we also recognize that not everyone can or will get there through lifestyle alone, and that leaving someone's blood pressure elevated while they "try harder" carries real, measurable risk. Every major hypertension guideline (ESC, AHA/ACC, and others) treats lifestyle and medication as complementary, not competing, strategies.
Obesity deserves the exact same logic — and for a long time, it didn't get it.
What the Research Actually Shows
This isn't a fringe or unproven treatment category. The clinical trial data behind these medications is substantial:
In the STEP trial program, semaglutide produced consistent weight loss of roughly 11–15% across a range of patient populations, with the large majority of participants achieving clinically meaningful weight loss.
In the SURMOUNT-1 trial, tirzepatide achieved dose-dependent weight loss of 15.0%, 19.5%, and 20.9% at its three dose levels.
In a head-to-head comparison (SURMOUNT-5), tirzepatide produced greater sustained weight loss than semaglutide over 72 weeks — 20.2% versus 13.7% — the first direct trial comparing the two.
The benefits go well beyond the number on the scale. The SELECT trial — a landmark cardiovascular outcomes study — found that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% compared to placebo, in people with overweight or obesity and existing cardiovascular disease who did not have diabetes. Notably, this benefit appeared to occur independently of how much weight patients actually lost — suggesting these medications may protect the heart and blood vessels directly, not just as a side effect of shedding pounds.
This is precisely the same category of benefit we already accept from hypertension medication: not just a number improving, but a real reduction in heart attacks, strokes, and death.
Even Doctors Underestimate These Medications
Here's something that surprised me when I came across it: a survey of 122 practicing physicians found that they significantly underestimated how well these medications work and significantly overestimated how commonly patients discontinue them. Fewer than half of physicians surveyed correctly recognized the cardiovascular benefit in patients without diabetes — worse than random guessing would have produced.
If practicing physicians are underestimating the evidence, it's no surprise the stigma is even more exaggerated in casual conversation, comment sections, and gym locker rooms.
Who I'm Actually Worried About
To be clear about something important: I am not worried about the patient who hears "that's cheating" and shrugs it off. If you understand what these medications do, why they work, and you've made an informed decision to use one — that's not cheating, that's medicine, and you don't need my reassurance.
The patient I am worried about is the one who doesn't have that context. The person who's quietly struggled with their weight for years, who has real cardiovascular risk factors, who might be an excellent candidate for real, guideline-supported benefit — and who talks themselves out of even asking their doctor about it because somewhere along the way they absorbed the idea that needing help here, unlike needing help for blood pressure or cholesterol or a dozen other conditions, makes them weak or lazy.
That's the person the stigma actually hurts. Not the person taking the medication — the person who's avoiding a conversation that could change their health trajectory, based on a comparison (diet and exercise "should" be enough) that we would never apply to any other chronic condition with a similar risk profile.
The Bottom Line
Lifestyle change matters. It's not a consolation prize you settle for when medication isn't available — it's foundational, and in hypertension, it can be the entire solution for some patients. The same is true for weight and metabolic health. But foundational doesn't mean sufficient for everyone, and it never has been, for any chronic condition we treat.
If you've been curious about whether a GLP-1 or GIP medication makes sense for you, the only stigma worth worrying about is the one that keeps you from asking the question.
Jeffrey Schnur, FNP-BC
Founder & Clinical Director, Apex Coastal Wellness
References
Wilding, J.P.H., et al. STEP 1 Trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
Jastreboff, A.M., et al. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.
Garvey, W.T., et al. SURMOUNT-5: Tirzepatide versus Semaglutide in Adults with Obesity. NEJM, 2026.
Lincoff, A.M., et al. SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM.
Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists. PMC, National Institutes of Health.
American Heart Association/American College of Cardiology 2025 Hypertension Guideline; European Society of Cardiology 2024 Hypertension Guideline.
